A peptide inhibitor based on the BCL-6 interaction peptide from SMRT has been shown to be effective against diffuse large B-cell lymphoma (DLBCL) in vitro and in mice models (Cerchietti et al., 2009). Here, BCL6 is linked to diffuse large B-cell lymphoma.